Identification of patients at risk for poor survival among those with normal skeletal muscle mass: a multicenter retrospective validation study in gastric cancer - Summary - MDSpire

Identification of patients at risk for poor survival among those with normal skeletal muscle mass: a multicenter retrospective validation study in gastric cancer

  • By

  • Ryota Matsui

  • Kazuyoshi Yamamoto

  • Yoshiro Yukawa

  • Masayoshi Terayama

  • Yukinori Kurokawa

  • Daisuke Ichikawa

  • Yoshitomo Yanagimoto

  • Takashi Oshima

  • Souya Nunobe

  • Takashi Kamei

  • Hiroya Takeuchi

  • Yoshihiro Nabeya

  • Masaki Kaibori

  • Naoki Hiki

  • Hidetoshi Eguchi

  • Yuichiro Doki

  • July 6, 2026

  • 0 min

Share

Objective:

To determine the cutoff value that predicts poor long-term survival among patients without low skeletal muscle mass.

Approach:
  • Study Design: A multicenter retrospective cohort study involving 17 hospitals in Japan, evaluating the association between preoperative skeletal muscle mass index (SMI) and clinical outcomes in gastric cancer patients undergoing radical gastrectomy.
  • Patient Selection: Patients diagnosed with gastric or esophagogastric junction adenocarcinoma were included, while those with low SMI, prior neoadjuvant therapy, or unsuitable conditions were excluded.
  • SMI Measurement: Skeletal muscle mass was assessed using preoperative CT scans, measuring the cross-sectional area of muscles at the third lumbar vertebra.
  • Statistical Analysis: Cox regression models were used to determine sex-specific cutoff values for SMI, and long-term survival was compared between high and r-low SMI groups.
Key Findings:
  • The study identified specific cutoff values for preoperative SMI that correlate with overall survival in patients without low skeletal muscle mass.
  • Patients with SMI below the cutoff were categorized as having relatively low SMI (r-low SMI) within the normal range.
Interpretation:

Limitations:
  • The study was retrospective and conducted in a single country, which may limit generalizability.
  • Patients with prior neoadjuvant therapy were excluded, potentially affecting the applicability of findings to a broader patient population.
Conclusion:

Original Source(s)

Related Content